Innate mechanisms can predict successful allergy immunotherapy - 05/02/16
Key words : Dendritic cells, allergen immunotherapy, biomarker, type 2 dendritic cell, regulatory dendritic cells
Le texte complet de cet article est disponible en PDF.
Disclosure of potential conflict of interest: L. O'Mahony has consultant arrangements with Alimentary Health and has received a grant from GlaxoSmithKline. C. A. Akdis has consultant arrangements with Actellion, Aventis, Stallergenes, Allergopharma, and Circacia; is employed by the Swiss Institute of Allergy and Asthma Research, University of Zurich; has received grants from Novartis, PREDICTA: European Commission's Seventh Framework programme no. 260895, the Swiss National Science Foundation, MeDALL: European Commission's Seventh Framework Programme No. 261357, and the Christine Kühne Center for Allergy Research and Education. T. Eiwegger declares that he has no relevant conflicts of interest. |
Vol 137 - N° 2
P. 559-561 - février 2016 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?